Lack of p53 augments antitumor functions in cytolytic T cells

Cancer Research

Volumn 76, Issue 18, 2016, Pages 5229-5240

  Banerjee, Anirban ^a,d   Thyagarajan, Krishnamurthy ^a   Chatterjee, Shilpak ^a   Chakraborty, Paramita ^a   Kesarwani, Pravin ^a   Soloshchenko, Myroslawa ^a   Al Hommrani, Mazen ^a   Andrijauskaite, Kristina ^a   Moxley, Kelly ^b   Janakiraman, Harinarayanan ^c   Scheffel, Matthew J ^a   Helke, Kristi ^a   Armenson, Kent ^a   Palanisamy, Viswanathan ^c   Rubinstein, Mark P ^a   Mayer, Elizabeth Garrett ^a   Cole, David J ^a   Paulos, Chrystal M ^a   Voelkel Johnson, Christina ^a   Nishimura, Michael I ^b   Mehrotra, Shikhar ^a   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUSED CARBON NITROGEN SULFUR HETEROCYCLE; GAMMA INTERFERON; PIFITHRIN ALPHA; PIFITHRIN MU; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MOUSE; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; SENESCENCE; TUMOR CELL DESTRUCTION; ANIMAL; C57BL MOUSE; DISEASE MODEL; FLOW CYTOMETRY; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; XENOGRAFT;

ADOPTIVE TRANSFER; ANIMALS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HETEROGRAFTS; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84988935322     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1798     Document Type: Article

References (46)

1. Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA. Adoptive cell therapy-tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin Oncol 2015;42:626-39.
2. Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, et al. Reducing CD73 expression by IL1beta-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res 2014;74:6048-59.
3. Kesarwani P, Al-Khami AA, Scurti G, Thyagarajan K, Kaur N, Husain S, et al. Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res 2014;74:6036-47.
4. Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, et al. Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death. Cancer Res 2009;69:6282-9.
5. Zuckerman V, Wolyniec K, Sionov RV, Haupt S, Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 2009;219:3-15.
6. Grayson JM, Lanier JG, Altman JD, Ahmed R. The role of p53 in regulating antiviral T cell responses. J Immunol 2001;167:1333-7.
7. Watanabe M, Moon KD, Vacchio MS, Hathcock KS, Hodes RJ. Down-modulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses. Immunity 2014;40:681-91.
8. Kawashima H, Takatori H, Suzuki K, Iwata A, Yokota M, Suto A, et al. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J Immunol 2013;191:3614-23.
9. Cordenonsi M, Dupont S, Maretto S, Insinga A, Imbriano C, Piccolo S. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 2003;113:301-14.
10. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006;126:107-20.
11. Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P, Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011;2:948-57.
12. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science 2013;342:1242454.
13. Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, et al. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self-immunity in mice. J Immunol 2012;189:1627-38.
14. Ferrick DA, Neilson A, Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 2008;13:268-74.
15. Chatterjee S, Eby JM, Al-Khami AA, Soloshchenko M, Kang HK, Kaur N, et al. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 2014;134:1285-94.
16. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol 2003;23:4713-27.
17. Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest 2013;123:5247-57.
18. Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 2015;16:393-405.
19. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008;65:3981-99.
20. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011;13:310-6.
21. Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci 2014;39:347-54.
22. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 2014;345:1250684.
23. Chang CH, Curtis JD, Maggi LBJr, Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013;153:1239-51.
24. + T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003;281:65-78.
25. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer 2012;12:671-84.
26. + tumor infiltrating lymphocyte. Cancer Res 1999;59:6230-8.
27. Oksanen A, Aittomaki S, Jankovic D, Ortutay Z, Pulkkinen K, Hamalainen S, et al. Proprotein convertase FURIN constrains Th2 differentiation and is critical for host resistance against Toxoplasma gondii. J Immunol 2014;193:5470-9.
28. Filen S, Ylikoski E, Tripathi S, West A, Bjorkman M, Nystrom J, et al. Activating transcription factor 3 is a positive regulator of human IFNG gene expression. J Immunol 2010;184:4990-9.
29. Duursma A, Agami R. p53-Dependent regulation of Cdc6 protein stability controls cellular proliferation. Mol Cell Biol 2005;25:6937-47.
30. Andres NC, Fermento ME, Gandini NA, Romero AL, Ferro A, Donna LG, et al. Heme oxygenase-1 has antitumoral effects in colorectal cancer: involvement of p53. Exp Mol Pathol 2014;97:321-31.
31. + T cell subsets. Nat Immunol 2011;12:1221-9.
32. Elston R, Inman GJ. Crosstalk between p53 and TGF-beta signalling. J Signal Transduct 2012;2012:294097.
33. Voorneveld PW, Kodach LL, Jacobs RJ, van Noesel CJ, Peppelenbosch MP, Korkmaz KS, et al. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br J Cancer 2015;112:122-30.
34. + T cells after priming in the absence of the cell cycle regulator E2F4. Cell Immunol 2009;257:44-54.
35. Ju S, Zhu Y, Liu L, Dai S, Li C, Chen E, et al. Gadd45b and Gadd45g are important for anti-tumor immune responses. Eur J Immunol 2009;39:3010-8.
36. Gupta M, Gupta SK, Hoffman B, Liebermann DA. Gadd45a and Gadd45b protect hematopoietic cells from UV-induced apoptosis via distinct signaling pathways, including p38 activation and JNK inhibition. J Biol Chem 2006;281:17552-8.
37. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
38. Muller PA, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013;15:2-8.
39. Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS One 2011;6:e22560.
40. Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006;38:431-40.
41. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 2014;41:116-26.
42. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300-5.
43. Rivera A, Maxwell SA. The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem 2005;280:29346-54.
44. Liu B, Chen Y, St Clair DK. ROS and p53: a versatile partnership. Free Radic Biol Med 2008;44:1529-35.
45. Zhao Y, Chaiswing L, Velez JM, Batinic-Haberle I, Colburn NH, Oberley TD, et al. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res 2005;65:3745-50.
46. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, et al. Control of T (H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011;146:772-84.